MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation.
Introduction
Regulation of the p53 tumor suppressor requires cooperation of MDM2 and MDMX oncoproteins. MDM2 and MDMX are homologs that share aminoacid sequence similarity in several domains (Shvarts et al., 1997) . MDM2 is an ubiquitin E3 ligase that promotes p53 ubiquitination and degradation. Although MDMX has very low E3 ligase activity, it forms heterodimer with MDM2 through the C-terminal RING domain and is believed to stimulate MDM2 activity under physiological conditions (Badciong and Haas, 2002; Gu et al., 2002; Linares et al., 2003) . In addition to regulating p53 ubiquitination, MDM2 interacts with several transcriptional regulators (such as p300, CBP, YY1, KAP1) and chromatin-modifying enzymes (such as HDAC1, SUV39H1, EHMT1, G9a). The recruitment of these factors may directly regulate p53 transcriptional activity at promoters. Recent studies have shown that MDM2 also induces p53 conformational change and inhibits p53 DNA binding (Sasaki et al., 2007; Cross et al., 2011) . Mouse models showed that the expression and E3 ligase activity of MDM2 are critical for preventing p53 hyperactivation and for ensuring survival of mouse embryos (Jones et al., 1995; Montes de Oca Luna et al., 1995; Itahana et al., 2007) .
The biochemical activities of MDM2 are under tight regulation. MDM2 E3 ligase activity is regulated by phosphorylation near the C-terminal RING domain, by interactions with several ribosomal proteins, and by the tumor suppressor ARF. MDM2 phosphorylation has a critical role in p53 activation by genotoxic stress such as ionizing irradiation and other inducers of DNA strand breaks (Cheng et al., 2009) . Ribosomal proteins such as L5, L11 and L23 bind to the MDM2 central acidic region and zinc finger to cause p53 accumulation when ribosomal RNA transcription or ribosome assembly is disturbed (Zhang and Lu, 2009 ). MDM2-L11 interaction is important for suppression of Myc-induced tumorigenesis in a mouse model (Macias et al., 2010) .
An important MDM2 regulator is the ARF tumor suppressor (Sherr, 2006) . ARF is encoded by an alternative open reading frame in the p16/INK4 locus. Oncogene activation induces ARF expression through transcriptional and post-translational mechanisms . ARF binds to the acidic region of MDM2 and inhibits p53 ubiquitination (Midgley et al., 2000) . Mice without ARF expression are predisposed to tumor development, showing significant overlap with phenotypes of p53-null mice (Kamijo et al., 1997) . ARF expression is lost in nearly all human tumors that retain wild-type p53, suggesting that ARF inactivation and p53 mutation are alternative mechanisms, each sufficient to disable the p53 pathway during tumor development (Stott et al., 1998) .
Despite its important biological roles, the mechanism by which ARF activates p53 is still poorly understood. ARF binds to a central acidic region of MDM2 that is predicted to be unstructured in the absence of binding partners. ARF sequence also predicts that it is an unstructured protein (Sherr, 2006) . Interaction between an ARF peptide and the MDM2 acidic region causes significant secondary structure formation in vitro (Bothner et al., 2001; Sivakolundu et al., 2008) . The acidic region of MDM2 is important for ubiquitination and degradation of p53 through unknown mechanisms (Meulmeester et al., 2003; Kawai et al., 2003b) .
Mouse models demonstrated that MDMX is a critical regulator of p53 during embryonic development (Parant et al., 2001) . MDMX in adult somatic tissues is less important for p53 regulation than is MDM2 (Grier et al., 2006; Xiong et al., 2006; Maetens et al., 2007) . Nonetheless, MDMX expression and phosphorylation by the ATM/Chk2 pathway have significant roles in p53 DNA damage response in adult mice (Terzian et al., 2007; Wang et al., 2009) . MDMX overexpression has been detected in tumors with wild-type p53 and presumably contributes to p53 inactivation (Ramos et al., 2001; Danovi et al., 2004; Laurie et al., 2006) . The MDMX level is controlled by MDM2-mediated ubiquitination in a stress-dependent manner (Pan and Chen, 2003; Kawai et al., 2003a) . Whereas MDM2 has a very short half-life (B30 min), MDMX is relatively stable in the absence of stress (half-life 3-6 h). Significant degradation of MDMX occurs after DNA damage or ribosomal stress induction. DNA damage induces phosphorylation of MDMX on several C-terminal sites (S342 and S367 by Chk2, S403 by ATM), with S367 phosphorylation being the most critical for promoting degradation by MDM2 (Chen et al., 2005; Pereg et al., 2005) . During ribosomal stress, L11 binding to MDM2 is important for promoting MDMX degradation . Artificially overexpressing MDMX or blocking MDMX degradation significantly dampens p53 response to stress, promoting tumor development (Wang et al., 2009; Xiong et al., 2010) . Therefore, key signaling mechanisms that block p53 degradation by MDM2 also simultaneously enhance MDMX degradation by MDM2. These observations underscore the coordinated control of MDM2 and MDMX by stress signals, which is critical for proper p53 response.
MDM2 is a classic p53 transcriptional target, forming a negative feedback loop (Wu et al., 1993) . Although MDMX was initially believed to be non-responsive to p53 transactivation, recent studies have identified bona fide p53-binding sites in intron 1 of the human MDMX gene and demonstrated that p53 activation can lead to moderate induction of MDMX transcription (Li et al., 2010; Phillips et al., 2010) . However, the magnitude of MDMX mRNA induction (1.5-3-fold) is much lower compared with that of MDM2 (410-fold) after p53 activation, and displayed cell-type specificity. These studies showed that MDMX is a p53 target gene that may also provide a negative feedback response to p53 activation.
MDM2 and MDMX N-terminal domains form a hydrophobic pocket and bind an amphipathic helix of p53. Several small-molecule disruptors of p53-MDM2 binding have been developed and showed promising anti-tumor activities (Vassilev et al., 2004; Shangary et al., 2008) . Owing to structural differences, current inhibitors of MDM2 have negligible effects on MDMXp53 binding, and are thus suboptimal for p53 activation in cells overexpressing MDMX (Hu et al., 2006; Patton et al., 2006; Wade et al., 2006; Shangary et al., 2008) . As MDM2-specific inhibitors can partially activate p53 which in turn induces MDM2 expression, these inhibitors should in theory promote MDMX degradation, thus bypassing the need for an MDMX inhibitor. However, several reports found that Nutlin treatment does not cause significant reduction in the MDMX level in tumor cell lines, and may even increase the MDMX level in certain cell lines due to p53-mediated induction of MDMX transcription (Hu et al., 2006; Wade et al., 2006; Li et al., 2010) . Interestingly, Nutlin induces significant MDMX reduction in non-transformed human cells (Wade et al., 2006) . These observations suggest important differences in the regulation of MDMX expression and degradation in normal and tumor cells.
In this report, we show that ARF is a key factor in regulating MDMX degradation by MDM2. The loss of ARF expression in tumor cells causes MDMX to display poor sensitivity to MDM2. Restoration of ARF expression enables MDM2 to bind and degrade MDMX in a dose-dependent manner. ARF acts by stimulating heterodimer formation between MDM2 and MDMX, thus increasing MDMX ubiquitination. These results showed that the loss of ARF expression during tumorigenesis results in a defect in MDMX degradation that further compromises p53 function.
Results

MDMX is resistant to MDM2 in tumor cells
To investigate whether normal and tumor cells display a difference in MDMX regulation by MDM2, we used Nutlin and MI-63 to treat a panel of human cells including normal human fibroblasts (HFF, WI-38) and tumor cells (U2OS, A549, 2102EP, 833KE, H1299, HCT116 and HCT116-p53
). Treatment of all p53 wild-type cells caused strong increase in MDM2 due to p53 activation. Increase in MDM2 was correlated with a significant decrease in the MDMX level in nontransformed HFF and WI-38 cells, but not in tumor cell lines (Figure 1a, Supplementary Figure 1) . Instead, certain tumor cell lines (such as HCT116, 2102EP, 833KE) showed a moderate increase in the MDMX level. As expected, Nutlin and MI-63 did not change MDM2 and MDMX levels in p53-null cells. Reverse transcriptase-PCR analysis showed that MDMX mRNA was induced after p53 activation to various degrees in different cell lines, ranging from no induction (WI-38, HFF), B30% (HCT116, U2OS), to 300-600% (2102EP, 833KE) (Figure 1b) . These results indicate that the increase in MDM2 is not sufficient to eliminate MDMX in tumor cells. Induction of MDMX mRNA may even lead to a net increase in the MDMX protein level. Furthermore, the significant downregulation of MDMX in Nutlin/MI-63-treated normal cells (WI-38, HFF) cannot be explained by changes in MDMX transcription, suggesting that regulation of MDMX turnover is different between normal and tumor cells (see Figure 3) .
It is noteworthy that a recent study showed that Nutlin treatment induces MDMX degradation in a significant number of tumor cell lines (including HCT116, A549) (Xia et al., 2008) . Our results above showed that MDMX in HCT116 and A549 were nonresponsive to Nutlin or MI-63. The reason for this discrepancy is still unclear. It is possible that we used lower concentrations of Nutlin (8 mM of a racemic mixture), whereas the Xia study used 10 mM of active Nutlin enantiomer. Strong p53 activation and MDM2 induction may lead to other cellular stress that facilitates MDMX degradation.
Proteasome-mediated MDMX degradation after MDM2 induction in normal cells
To determine whether deficiency in MDMX degradation accounts for the inability of tumor cells to downregulate MDMX, we focused on HFF and U2OS as representative normal and tumor cell lines, respectively. Nutlin treatment reduced the MDMX level in HFF cells in a dose-dependent manner, but slightly induced MDMX in U2OS (Figure 2a ). Inhibition of proteasome by MG132 blocked MDMX downregulation by Nutlin in HFF cells (Figure 2b ), suggesting that MDMX reduction was due to proteasome-mediated degradation. In contrast, the MDMX level in U2OS and HCT116 showed little response to MG132, indicating relatively stable MDMX before and after MDM2 induction ( Figure 2c ).
Tumor cells typically have a higher MDMX expression level than do non-transformed cells. It is possible that excess MDM2 in normal cells allows MDMX degradation, whereas excess MDMX in tumor cells saturates the capacity of MDM2. To test this possibility, lentivirus MDMX was used to stably infect HFF to increase its MDMX level by 8-fold, 42-fold higher than tumor cells such as HCT116 and U2OS, Supplementary  Figure 2a ). When treated with Nutlin, HFF-MDMX cells still showed significant MDMX degradation compared with parental cells (Figure 2d ), suggesting that normal cells are inherently more capable in degrading MDMX.
MDMX sensitivity to MDM2 is different between normal and tumor cells
To determine whether decreases in MDMX in Nutlintreated HFF and WI-38 cells were due to accelerated degradation, MDMX degradation rate was analyzed by cycloheximide block. The results showed that MDMX was stable in untreated WI-38 and HFF, but became unstable after Nutlin treatment (Figures 3a and b) . In contrast, Nutlin did not induce MDMX degradation in U2OS cells (Figure 3c ). To further test the effect of MDM2 expression without using Nutlin treatment, WI-38 and U2OS cells were infected with the MDM2 adenovirus. The result showed that increased MDM2 expression in HFF also led to MDMX degradation, whereas MDM2 expression in U2OS had a negligible effect on the MDMX level ( Figure 3d ).
A previous study has shown that DNA damage promotes MDMX degradation without inducing the MDM2 level, suggesting that phosphorylation of MDMX increases its sensitivity to MDM2 (Chen et al., 2005) . As expected, g-irradiation promoted MDMX degradation in U2OS cells, despite inducing lower MDM2 level than Nutlin. Combination of irradiation and Nutlin resulted in further reduction of the MDMX level ( Figure 3e ). Therefore, simply increasing the MDM2 level in U2OS was not effective in degrading MDMX. An additional stress signal such as DNA damage was required to trigger MDMX degradation.
DNA damage promotes MDMX degradation mainly by Chk2-mediated phosphorylation of S367. The MDMX-367A mutant is resistant to DNA damageinduced degradation (Chen et al., 2005) . We found that stably expressed MDMX-367A was still efficiently degraded in HFF cells after Nutlin treatment (data not shown), thus ruling out a role of MDMX phosphorylation in its sensitivity to MDM2 in normal cells. Taken together, the results suggest that MDMX is sensitive to MDM2 in normal cells, but is relatively resistant to MDM2 in tumor cells. The results also suggest an important change in MDMX regulation during the transformation process.
ARF expression promotes MDMX degradation in tumor cells
A key difference between normal cells and tumor cells with wild-type p53 is the loss of ARF expression due to deletion or silencing of the INK4 locus. To test whether ARF expression in tumor cells restores MDMX sensitivity to MDM2, a U2OS cell line expressing isopropyl b-D-1-thiogalactopyranoside (IPTG)-inducible ARF (NARF6) was used (Stott et al., 1998) . U2OS cells have deletion of the INK4 locus and are devoid of endogenous ARF (Stott et al., 1998 ). Induction of high-level MDM2 alone by Nutlin did not reduce the MDMX level in NARF6 cells, similar to the parental U2OS. Induction of ARF by IPTG resulted in p53 activation, MDM2 induction and moderate reduction of the MDMX level. Importantly, simultaneous induction of MDM2 and ARF led to significant reduction of MDMX (Figure 4a) . A cycloheximide block experiment showed that MDMX degradation was accelerated after ARF expression (Figure 4b ). The effect of ARF was observed at expression levels similar to endogenous ARF in p53-null H1299 cells (Supplementary Figure 3) , suggesting that it can occur at physiological ARF levels. These results suggest that ARF cooperates with MDM2 to regulate MDMX stability.
Next, we tested whether endogenous ARF expression in non-transformed cells contributes to MDMX sensitivity to MDM2. First, we compared MDMX degradation in mouse embryo fibroblasts (MEFs) derived from wild-type and ARF-null mice. The result showed that in the absence of Nutlin treatment, MDMX was more stable in ARF-null MEF than in wild-type MEF (Figure 4c ). Furthermore, Nutlin treatment led to more complete MDMX degradation in wild-type MEF than in ARF-null MEF (Figure 4d ). In contrast, g-irradiation reduced the MDMX level in both cell lines (Supplementary Figure 2c) . In the second experiment, stable knockdown of endogenous ARF in HFF cells using shRNA also led to stabilization of endogenous MDMX after Nutlin treatment (Supplementary Figure  2d) . Therefore, the loss of ARF expression reduces MDMX sensitivity to MDM2, suggesting that ARF is an important regulator of MDMX degradation in the absence of DNA damage signals. MDMX degradation facilitates cell-cycle arrest by ARF To test the functional significance of MDMX degradation in ARF-mediated cell-cycle arrest, modified U2OS cell lines expressing high, normal or reduced levels of MDMX were infected with ARF adenovirus. The ARF expression in U2OS inhibited cell proliferation but did not induce apoptosis (not shown). The cell-cycle arrest by ARF measured by bromodeoxyuridine incorporation assay was significantly enhanced by knockdown of endogenous MDMX, whereas MDMX-overexpressing cells were completely resistant to ARF-induced arrest (Figure 5b ). Western blot analysis showed that U2OS-MDMX cells maintained a high MDMX level after ARF expression, despite partial degradation. MDMX overexpression did not prevent p53 stabilization by ARF, but blocked p21 induction by p53 (Figure 5a ). Furthermore, MDMX knockdown enhanced p21 induction without increasing p53 level, suggesting that MDMX controls p53 transcriptional activity but not stability in this setting. Therefore, the MDMX level has a significant impact on p53 response to ARF. Efficient p53 activation by ARF requires both p53 stabilization (inhibition of MDM2) and elimination of MDMX.
ARF stimulates MDMX ubiquitination and degradation by MDM2
Our previous study showed that ARF expression promotes MDMX ubiquitination by MDM2 (Pan and Chen, 2003) . However, as ARF also simultaneously induced MDM2 stabilization, it was unclear whether it acts simply by increasing MDM2 dosage. The result in Figure 4a suggests that ARF functions through a mechanism different from MDM2 stabilization, as a much higher MDM2 level induced by Nutlin failed to degrade MDMX. To test whether ARF stimulates MDMX ubiquitination by increasing MDM2-specific activity, H1299 cells were transfected with MDMX, MDM2 and His6-ubiquitin. MDMX ubiquitination was detected by Ni-NTA pull down, followed by MDMX western blot. MDM2 expression levels in the absence and presence of ARF were matched by reducing the amount of MDM2 plasmids cotransfected with ARF to compensate for stabilization. The results showed that increasing the ARF level moderately above the endogenous level increased the high-molecular-weight form of ubiquitinated MDMX, suggesting that ARF stimulates MDMX poly-ubiquitination by MDM2 (Figure 6a ). The moderate effect of exogenous ARF in this assay is probably due to the presence of endogenous ARF in H1299 cells, and the interference of MDMX phosphorylation from transfection stress (Okamoto et al., 2005) . Therefore, we performed the assay using the phosphorylation-resistant MDMX-367A mutant in ARF-deficient U2OS cells. As reported previously, poly-ubiquitination of MDMX-367A was inefficient even with high doses of MDM2. Coexpression of ARF resulted in efficient poly-ubiquitination of MDMX-367A in an MDM2 dose-dependent manner (Figure 6b ). MDMX-367A is resistant to degradation by MDM2 after DNA damage or in a cotransfection assay due to resistance to phosphorylation by Chk2 (Chen et al., 2005) . However, cotransfection of ARF led to efficient MDMX-367A degradation by MDM2 (Figure 6c ). The ARF expression also stimulated poly-ubiquitination of the MDMX-342A-367A-403A triple mutant without Chk2 and ATM phosphorylation sites (Supplementary Figure 4a) . These results demonstrate that ARF stimulates MDMX ubiquitination through a mechanism different from the phosphorylation-dependent pathway after DNA damage.
ARF promotes MDMX-MDM2 binding
To determine how ARF stimulates MDMX ubiquitination, an in vitro ubiquitination reaction was performed using recombinant His6-MDM2 and in vitro-translated MDMX. An ARF N-terminal 20 amino-acid peptide (ARF20) and a scrambled peptide with the same aminoacid composition (R20) were added to the reaction to test the effect on MDMX ubiquitination. The ARF20 peptide has been shown to be functionally equivalent to full-length ARF in p53 activation in vivo, and inhibition of p53 ubiquitination in vitro (Midgley et al., 2000) . The result showed that the ARF20 but not the R20 peptide stimulated MDMX ubiquitination (Figure 7a ), indicating that the effect of ARF can be recapitulated in vitro using the ARF20 peptide.
To identify the step in the ubiquitination reaction that was stimulated by ARF, MDM2 was immunoprecipitated from SJSA cells and the loaded beads were used to capture in vitro-translated MDMX. The pre-formed MDM2-MDMX complex was then incubated with E1, E2 and ubiquitin to initiate the ubiquitination reaction. ARF20 was added during the MDMX-binding step, or after binding. The results showed that the ARF20 peptide significantly increased the binding of MDMX to immobilized MDM2, resulting in more MDMXubiquitin product in the subsequent ubiquitination reaction (Figure 7b ). In contrast, if the peptide was added after MDMX capture, no increase in MDMX ubiquitination was detected. Therefore, we conclude that the ARF20 peptide stimulates MDMX ubiquitination by enhancing MDMX-MDM2 binding.
To test whether ARF also stimulates MDMX-MDM2 binding in vivo, its effect was examined in U2OS cells. ARF expression increased the co-precipitation of transfected MDMX with MDM2 (Figure 8a ). Endogenous MDMX-MDM2 binding was also stimulated by ARF after IPTG induction in NARF6 cells (Figure 8b ). Furthermore, in the absence of ARF, highlevel MDM2 expression only resulted in a small increase in MDM2-MDMX complex formation, whereas after ARF expression, MDM2-MDMX binding became proportional to the dose of MDM2 (Figure 8c ). These results suggest that ARF is a critical cofactor that allows MDM2 to bind and degrade MDMX efficiently in the absence of DNA damage.
ARF stimulates a second-site interaction between MDM2 and MDMX To determine how ARF stimulates the MDM2-MDMX interaction, we first tested whether ARF interacts with MDMX. Coexpression of ARF with similar amounts of FLAG-MDM2 and FLAG-MDMX showed that only MDM2 was capable of coprecipitating with ARF ( Supplementary Figure 4b) , consistent with a previous report (Wang et al., 2001) . This suggests that ARF acts by binding MDM2 and increasing its affinity to MDMX.
The MDM2-MDMX interaction is mainly mediated by the C-terminal RING domains (Tanimura et al., 1999; Dang et al., 2002; Linke et al., 2008) . Unexpectedly, we found that the central region of MDM2 (MDM2-100-361) without the RING domain showed efficient binding to MDMX when coexpressed with ARF. As expected, in the absence of ARF, MDM2-100-361 did not bind MDMX (Figure 9a ). Further tests showed that MDM2-100-361 was coprecipitated MDMX-100-361 in the presence of ARF (Figure 9b ). Additional mapping experiments using epitope-tagged MDM2 and MDMX fragments showed that the MDM2 acidic domain (200-300), and the MDMX central region containing the acidic domain plus zinc finger (100-361) are important for ARF-mediated binding (Supplementary Figure 5 ). These results suggest that ARF stimulates a novel interaction between MDM2 and MDMX central region, independent of the well-characterized binding interface between C-terminal RING domains (Figure 10 ). This second-site interaction further stabilizes the MDM2-MDMX heterodimer, promoting MDMX degradation.
Discussion
MDM2 is an E3 ligase capable of degrading MDMX in a signal-dependent manner. Previous studies have found that endogenous MDMX is a stable protein in tumor cells; strong insults such as ionizing irradiation or actinomycin D treatment are required to trigger MDMX degradation (Chen et al., 2005; Gilkes et al., 2006) . MDM2-specific inhibitors activate p53 and in turn induce high-level MDM2 expression. Presumably, MDM2 induction should lead to degradation of MDMX, bypassing the need for an MDMX inhibitor. However, our results clearly show that MDMX in various tumor cells is insensitive to changes in the MDM2 level, which is different from normal cells. A previous study compared two other human fibroblast cell lines with tumor cells and also showed a difference in MDMX regulation after Nutlin treatment (Wade et al., 2006) . Taken together, these observations indicate the presence of a general phenomenon that has biological and clinical relevance.
Our findings suggest that at least two mechanisms contribute to the inability of the MDM2 inhibitors to downregulate MDMX in tumor cells. First, MDMX is more inducible by p53 at the transcriptional level in tumor cells than in normal fibroblasts, resulting in higher MDMX protein level in certain tumor cell lines after p53 activation. Furthermore, there is significant cell-type specificity in p53 sensitivity, that is, testicular germ cell tumors (2102EP, 833KE) have more inducible MDMX than other tumor cell lines. The mechanism of this cell-type dependence is still not understood. One possibility is the chromatin status of the MDMX P2 promoter may be different in each cell type. Presumably, the less-differentiated epigenetic profile of germ cell tumors or the presence of certain transcription factors may be responsible for higher p53 sensitivity. The second, possibly more important mechanism of MDMX misregulation in tumors is ARF deficiency. The loss of ARF during transformation not only disrupts mitogenic stress signaling to MDM2 but also leads to a defect in MDMX degradation. The ARF expression renders MDMX highly sensitive to changes in MDM2 levels in part by promoting MDM2-MDMX binding. In the absence of ARF, MDMX becomes resistant to MDM2-mediated degradation and loses response to changes in the MDM2 level. The coordinated control of two key p53 regulators may be essential for ARF to activate p53 in normal cells. Interestingly, the current findings and previous studies together show that oncogenic stress, DNA damage and ribosomal stress all inhibit MDM2 ubiquitination of p53 while stimulating MDMX ubiquitination. This common effect may be evolved to ensure efficient activation of p53 during different stress responses. Hyperactive MDM2 and stabilized MDMX in ARF-deficient tumors cooperate to block p53 response to oncogenic stress, thus acting as an alternative to p53 mutation.
Our results suggest that ARF regulates MDMX degradation by binding specifically to the MDM2 acidic region and initiating a second-site interaction between the central regions of MDM2 and MDMX. The secondary interaction cooperates with RING-mediated heterodimerization to further stimulate MDMX degradation. The acidic regions of MDM2 and MDMX are intrinsically unstructured in the absence of binding partners. The ARF sequence also has features of an unstructured protein. Interaction between an ARF peptide and the MDM2 acidic region causes significant secondary structure formation in vitro (Bothner et al., 2001; Sivakolundu et al., 2008) . Therefore, our results are consistent with a model that ARF induces a change of MDM2 acidic domain conformation, so that it becomes compatible for interacting with the central region of MDMX (Figure 10 , left branch). Alternatively, initial ARF-MDM2 interaction may cause ARF to adopt a structure competent for MDMX binding. Thus, ARF may act as a mediator to stabilize the MDM2-MDMX heterodimer (Figure 10, right branch) . This scenario is favored as the two acidic domains may not directly interact because of strong negative charges, whereas ARF will provide the positive charges required to form a stable trimeric complex.
It is a well-established fact that ARF not only prevents p53 degradation but counter-intuitively also causes MDM2 stabilization and accumulation. Our results suggest that MDM2 accumulation induced by ARF may serve to promote MDMX degradation, that is, ARF modulates and re-targets MDM2 E3 activity to further facilitate p53 activation. Therefore, MDM2 can exert negative and positive effects on p53 activity, depending on whether the cells are under stress. This intricate mechanism may explain the ability of ARF to function as key regulator of p53 and its obligatory loss during the development of tumors that express wild-type p53.
The abnormal MDMX regulation in tumor cells has direct clinical relevance. MDM2-specific inhibitors are currently being tested in clinical trials (Millard et al., 2011) . These compounds are designed to target tumors with wild-type p53. This population has invariably lost ARF expression because of deletion or gene silencing. P53 activation by targeting MDM2 alone in such tumors will be suboptimal, or may be ineffective in cases with MDMX overexpression. Targeting MDMX may substantially improve the efficacy of MDM2 inhibitors.
Materials and methods
Cell lines and reagents
The following cell lines were used in the study: A549 (lung tumor), H1299 (lung tumor, p53-null), U2OS (osteosarcoma), HCT116 (colon carcinoma), 2102EP and 833KE (testicular germ cell tumor), WI-38 (human lung fibroblast) and HFF (human foreskin fibroblast), MEF. 833KE and 2102EP cells were provided by Dr Stuart Lutzker. NARF6 (U2OS-expressing IPTG-inducible p14ARF) was provided by Dr Dawn Quelle. ARF-null MEF was provided by Dr Yanping Zhang. Cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. All MDM2 and MDMX constructs used in this study were human cDNA clones. Nutlin was purchased from Cayman Chemical (Ann Arbor, MI, USA). MI-63 was re-synthesized based on published structure (Ding et al., 2006) . Nutlin and MI-63 were used at 5-10 mM. HFF cells with stable expression of MDMX were generated by infection with MDMX lentivirus and selection of pooled cell line. Stable knockdown of ARF was performed using an ARF shRNA retrovirus (V2HS_195839) obtained from Open Biosystems (Huntsville, AL, USA). Cell proliferation was measured using the bromodeoxyuridine labeling and detection kit III (Roche, Indianapolis, IN, USA).
Protein analysis
To detect proteins by western blot, cells were lysed in lysis buffer (50 mM Tris-HCl (pH 8.0), 5 mM EDTA, 150 mM NaCl, 0.5% NP40, 1 mM phenylmethylsulfonyl fluoride, 50 mM NaF) and centrifuged for 5 min at 10 000 g. Cell lysate (10-50 mg protein) was fractionated by SDS-PAGE and transferred to Immobilon P filters (Millipore, Billerica, MA, USA). The filter was blocked for 1 h with phosphate-buffered saline containing 5% non-fat dry milk, 0.1% Tween-20. The following monoclonal antibodies were used: 4B2 and 2A9 for full-length MDM2 IP (Chen et al., 1993) , 3G9 for western blot of fulllength MDM2 and 4B11 for western blot of MDM2 C-terminal fragment, DO-1 (Pharmingen, Franklin Lakes, NJ, USA) for p53 western blot, 8C6 antibody for MDMX western blot and IP (Li et al., 2002) , rabbit polyclonal MDMX antibody for western blot of MDMX deletion mutants, 2A10 for mouse MDM2 western blot and 7A8 for mouse MDMX western blot. Both p14ARF and p19ARF antibodies were purchased from Neomarkers (Kalamazoo, MI, USA) and Abcam (Cambridge, MA, USA), respectively. The filter was developed using Supersignal (Thermo Scientific, Kalamazoo, MI, USA) or ECL-plus reagent (Amersham, Piscataway, NJ, USA).
Quantitative real-time PCR Cells were treated with 8 mM Nutlin, 8 mM MI-63 for 16 h or 10 Gy IR for 4 h and mRNA was extracted using RNeasy Mini kit (Qiagen, Valencia, CA, USA). Approximately 3 mg mRNA was used as template for reverse transcription by using SuperScript III First-Strand synthesis System (Invitrogen, Carisbad, CA, USA). The products were used for real-time PCR using the following primer pairs: MDMX 5 0 -GCCT TGAGGAAGGATTGGTA and 5 0 -TCGACAATCAGGGA CATCAT; MDM2 5 0 -CCCTTAATGCCATTGAACCT and 5 0 -CATACTGGGCAGGGCTTATT; Actin 5 0 -GCTCGTCG TCGACAACGGCTC and 5 0 -CAAACATGATCTGGGTCA TCTTCTC. The relative levels of target genes were determined using actin as an internal control.
In vivo ubiquitination assay U2OS cells in 10-cm plates were transfected with 5 mg His6-ubiquitin, 5 mg MDMX or MDMX-367A, 1-2 mg MDM2 or MDM2 mutants and 1 mg p14ARF expression plasmids using calcium phosphate precipitation method. Thirty-two hours after transfection, cells from each plate were collected into two aliquots. One aliquot (10%) was used for direct western blot. The remaining cells (90%) were used for purification of His6-tagged proteins by Ni 2 þ -NTA beads. The cell pellet was lysed in buffer A (6 M guanidinium-HCl, 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , 0.01 M Tris-Cl pH 8.0, 5 mM imidazole, 10 mM b-mecaptoethanol) and incubated with Ni 2 þ -NTA beads (Qiagen) for 4 h at room temperature. The beads were washed with buffer A, B (8 M urea, 0.1 M Na 2 PO 4 /NaH 2 PO 4 , 0.01 M Tris-Cl pH 8.0, 10 mM b-mecaptoethanol), C (8 M urea, 0.1 M Na 2 PO 4 /NaH 2-PO 4 , 0.01 M Tris-Cl pH 6.3, 10 mM b-mecaptoethanol), and bound proteins were eluted with buffer D (200 mM imidazole, 0.15 M Tris-Cl pH 6.7, 30% glycerol, 0.72 M b-mercaptoethanol, 5% SDS). The eluted proteins were analyzed by western blot for the presence of conjugated MDMX.
In vitro ubiquitination assay SJSA cells were treated with 8 mM Nutlin for 16 h, and then treated with 30 mM MG132 for 4 h. MDM2 was immunoprecipitated with the 4B2 antibody. The substrate MDMX was produced by in vitro translation in rabbit reticulocyte lysate using the TNT system (Promega, Madison, WI, USA) in the presence of 35 S-methionine. In all, 15 ml packed protein A beads loaded with MDM2 from a 15-cm plate of SJSA cells were washed with lysis buffer and reaction buffer (50 mM Tris pH 7.5, 2.5 mM MgCl 2 , 15 mM KCl, 1 mM DTT, 0.01% Triton X-100, 1% glycerol), incubated with 10 ml in vitro-translated MDMX, with or without ARF20 peptide (MVRRFLVTLRIRRACGPPRV) or R20-scrambled peptide (ALVRTRFRVRRPCVMLGPIR) for 2 h at 4 1C, and washed with reaction buffer. The beads loaded with the MDM2-MDMX complex were incubated with 100 ng purified human ubiqutin-activating enzyme His6-E1, 250 ng His6-Ubc5Hb ubiquitin-conjugating enzyme, 5 mg ubiquitin (Biomol, Farmingdale, NY, USA) and 20 ml reaction buffer in the presence of 4 mM ATP. The mixture was incubated at 37 1C for 2 h with shaking, boiled in SDS sample buffer and fractionated by SDS-PAGE. The gel was dried and MDMX was detected by autoradiography.
